Benjamin A. Teply

6.8k citations

53 papers · 4.1k indexed · 3 hit papers · h-index 20

Impact in

Biomaterials top 0.5%
- Nanoparticle-Based Drug Delivery
Pharmaceutical Science top 0.5%
- Advanced Drug Delivery Systems

Papers in

Pulmonary and Respiratory Medicine 33
- Prostate Cancer Treatment and Research 29
- Prostate Cancer Diagnosis and Treatment 10
Oncology 18
- PARP inhibition in cancer therapy 7
- Cancer Immunotherapy and Biomarkers 7

Co-authors: Omid C. Farokhzad Róbert Langer Jianjun Cheng Sangyong Jon Frank Gu Philip W. Kantoff Jerome P. Richie Etgar Levy‐Nissenbaum
Journals: Journal of Clinical Oncology (13 papers)The Prostate (3 papers)Biomaterials (3 papers)Cancers (2 papers)Cancer Letters (2 papers)
Partner nations: United States South Korea Germany

In The Last Decade

Benjamin A. Teply

48 papers receiving 4.1k citations

Hit Papers

align trajectories log scale

Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers 2008 · 577 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2008 Proceedings of the National Academy of Sciences
2006 Proceedings of the National Academy of Sciences
2006 Biomaterials

Peers

Countries citing papers authored by Benjamin A. Teply

Since Specialization

Citations

This map shows the geographic impact of Benjamin A. Teply's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin A. Teply with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin A. Teply more than expected).

Fields of papers citing papers by Benjamin A. Teply

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin A. Teply. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin A. Teply. The network helps show where Benjamin A. Teply may publish in the future.

Co-authors

The 25 scholars most cited alongside Benjamin A. Teply, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Benjamin A. Teply Line = papers co-authored together Benjamin A. Teply links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Abiraterone vs Enzalutamide Among US Veterans With Metastatic Hormone-Sensitive Prostate Cancer JAMA Network Open ·Harshraj Leuva, Mengxi Zhou, Benjamin A. Teply, Shorouk Thabet Ahmed, Carol Luhrs, Prabhjot S. Mundi, Susan E. Bates, Izak Faiena, Tito Fojo, Martin W. Schoen	2025	0
2	Assessment of PARP1 mRNA expression as prognostic of aggressive pathology and adverse outcomes, and as predictor of response to PARP inhibition in castration-sensitive prostate cancer. Journal of Clinical Oncology ·Emmanuel S. Antonarakis, Mohammed Alshalalfa, Benjamin A. Teply, Yangyang Hao, J. Proudfoot, Elai Davicioni, Edward M. Schaeffer, R. Jeffrey Karnes, Daniel E. Spratt, Justin H. Hwang, Tamara L. Lotan, Catherine H. Marshall	2025	2
3	Diagnosis of Metastatic Non-Small Cell Lung Cancer during Hospitalization: Missed Opportunity for Optimal Supportive Care? Cancers ·Chiara Fabi, Koustav Bhar, Elizabeth Lyden, 浩一浦田, Samia Asif, Omar Abughanimeh, Benjamin A. Teply	2024	0
4	Predictive Value of Multiparametric Magnetic Resonance Imaging in Risk Group Stratification of Prostate Adenocarcinoma Advances in Radiation Oncology ·A.S.H. Bai, Lucy D'Auvergne, Linda My Huynh, Nikola Lazic, R.V. Shabrov, Benjamin A. Teply, Charles A. Enke, Chad A. LaGrange, Michael J. Baine	2024	0
5	Androgen receptor inhibition suppresses anti-tumor neutrophil response against bone metastatic prostate cancer via regulation of TβRI expression Cancer Letters ·Titaporn Wannaprasert, Diane Costanzo-Garvey, Benjamin A. Teply, S. Paloscia, Runxia Zhang, Zachary T. Herbert, Colm Morrissey, Alicia J. Dafferner, Maher Y. Abdalla, Rachel W. Fallet, Tammy Kielian, Heather Jensen‐Smith, 澤田匡人, Keqiang Chen, Ian A. Bettencourt, Ji Ming Wang, Daniel W. McVicar, Juan Loeck Hernández, Fang Yu, Leah M. Cook	2023	15
6	Comparison of sequential versus concurrent chemoradiation regimens in non-metastatic muscle-invasive bladder cancer Radiation Oncology Journal ·Muhammad Adil Mutaqqin, G. L. Deeg, Runqiu Wang, Lynette M. Smith, Charles A. Enke, Raymond C. Bergan, Benjamin A. Teply, Michael J. Baine	2023	1
7	A case of metastatic adenoid cystic (basal cell) carcinoma of the prostate: Systemic therapy for a rare disease The Prostate ·Koustav Bhar, Subodh M. Lele, Benjamin A. Teply	2023	0
8	Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy. Journal of Clinical Oncology ·Catherine H. Marshall, Benjamin A. Teply, Su Jin Lim, Hao Wang, Shifeng Mao, William Kevin Kelly, Channing J. Paller, Mark C. Markowski, Samuel R. Denmeade, Michael A. Carducci, Mario A. Eisenberger, Serina King, Rana Sullivan, Tamara L. Lotan, Emmanuel S. Antonarakis	2023	4
9	Neuropilin-2 axis in regulating secretory phenotype of neuroendocrine-like prostate cancer cells and its implication in therapy resistance Cell Reports ·Muneo Maeda, 宮城茂, E E Vidotti, Richie Zweigenhaft, Zhengdong Hong, D. DeNio, 林忠平, Alyssa Bouska, Brendas . Speer, Ahmed M. Said, Lynette M. Smith, Benjamin A. Teply, Michael H. Muders, Surinder K. Batra, Kaustubh Datta, Samikshan Dutta	2022	9
10	Current Management of Refractory Germ Cell Tumors Current Oncology Reports ·Omar Abughanimeh, Benjamin A. Teply	2021	3
11	Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU‐AA‐302 The Prostate ·Benjamin A. Teply, Fang Qiu, Emmanuel S. Antonarakis, Michael A. Carducci, Samuel R. Denmeade	2019	3
12	Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study The Lancet Oncology ·Benjamin A. Teply, Hao Wang, Brandon Luber, Rana Sullivan, Robiatul Adawiyah, Ashley Bruns, Avery Spitz, LaTasha K. Clay, Victoria J. Sinibaldi, Caelan Golledge, Changxue Lu, John L. Silberstein, Jun Luo, Michael T. Schweizer, Charles G. Drake, Michael A. Carducci, Channing J. Paller, Emmanuel S. Antonarakis, Mario A. Eisenberger, Samuel R. Denmeade	2017	137
13	Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer Current Opinion in Endocrinology Diabetes and Obesity ·Benjamin A. Teply, Emmanuel S. Antonarakis	2016	16
14	Human Herpesvirus 8–Related Primary Effusion Lymphoma After Liver Transplantation American Journal of Transplantation ·Eric S. Christenson, Benjamin A. Teply, Vineet Agrawal, Peter B. Illei, Ahmet Gürakar, Jennifer A. Kanakry	2015	12
15	Systemic therapy for bladder cancer – a medical oncologist’s perspective PubMed ·Benjamin A. Teply, Jaeyeon Kim	2014	17
16	Novel treatment strategy for refractory hemorrhagic cystitis following radiation treatment of genitourinary cancer Lasers in Medical Science ·Dharam Kaushik, Benjamin A. Teply, George P. Hemstreet	2012	13
17	Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers Proceedings of the National Academy of Sciences ·Frank Gu, Liangfang Zhang, Benjamin A. Teply, Nina Mann, Andrew Z. Wang, Aleksandar F. Radovic‐Moreno, Róbert Langer, Omid C. Farokhzad Hit paper breakdown →	2008	577
18	Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proceedings of the National Academy of Sciences ·Omid C. Farokhzad, Jianjun Cheng, Benjamin A. Teply, N. Liyanagunawardhana, Sangyong Jon, Philip W. Kantoff, Jerome P. Richie, Róbert Langer Hit paper breakdown →	2006	1353
19	Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug delivery Biomaterials ·Jianjun Cheng, Benjamin A. Teply, N. Liyanagunawardhana, Joseph J.�Y. Sung, Gaurav Luther, Frank Gu, Etgar Levy‐Nissenbaum, Abere Sarah, Róbert Langer, Omid C. Farokhzad Hit paper breakdown →	2006	1020
20	Magnetically Responsive Polymeric Microparticles for Oral Delivery of Protein Drugs Pharmaceutical Research ·Jianjun Cheng, Benjamin A. Teply, Raul‐Alexandru Todika, 隆長沢, Dennis Chun‐Yu Ho, N. Liyanagunawardhana, Sangyong Jon, Omid C. Farokhzad, Ali Khademhosseini, Róbert Langer	2005	107

About Benjamin A. Teply

Benjamin A. Teply is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging and Biomaterials, having authored 53 papers that have together received 4.1k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (29 papers), Prostate Cancer Diagnosis and Treatment (10 papers), Radiopharmaceutical Chemistry and Applications (8 papers), PARP inhibition in cancer therapy (7 papers), Cancer Immunotherapy and Biomarkers (7 papers), RNA Interference and Gene Delivery (6 papers), Bladder and Urothelial Cancer Treatments (6 papers) and Nanoparticle-Based Drug Delivery (5 papers). The work is most often cited by research in Biomaterials (1.9k citations), Pharmaceutical Science (413 citations), Biomedical Engineering (1.4k citations), Molecular Biology (1.8k citations) and Molecular Medicine (131 citations). Benjamin A. Teply has collaborated with scholars based in United States, South Korea and Germany. Frequent co-authors include Omid C. Farokhzad, Róbert Langer, Jianjun Cheng, Sangyong Jon, Frank Gu, Philip W. Kantoff, Jerome P. Richie, Etgar Levy‐Nissenbaum, Gaurav Luther and Róbert Langer. Their work appears in journals such as Journal of Clinical Oncology, The Prostate, Biomaterials, Cancers and Cancer Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact